Screening for cystic fibrosis-related diabetes: A systematic review

Health Technology Assessment

Volumn 16, Issue 24, 2012, Pages 1-179

  Waugh, N ^a,c   Royle, P ^a,c   Craigie, I ^d   Ho, V ^a   Pandit, L ^a   Ewings, P ^e   Adler, A ^f   Helms, P ^b   Sheldon, C ^g  

^a Department of Public Health and Aberdeen ^*  (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c UNIVERSITY OF WARWICK   (United Kingdom)

^d ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^e MUSGRAVE PARK HOSPITAL   (United Kingdom)

^f ADDENBROOKE S HOSPITAL   (United Kingdom)

^g ROYAL DEVON AND EXETER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE;

BLOOD GLUCOSE MONITORING; COST EFFECTIVENESS ANALYSIS; CYSTIC FIBROSIS RELATED DIABETES MELLITUS; DIABETES MELLITUS; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; EARLY DIAGNOSIS; EVIDENCE BASED MEDICINE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INSULIN TREATMENT; LUNG DISEASE; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SCREENING; SCREENING TEST; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

BLOOD GLUCOSE; CYSTIC FIBROSIS; DIABETES MELLITUS; DISEASE PROGRESSION; GENETIC PREDISPOSITION TO DISEASE; GLUCOSE TOLERANCE TEST; GREAT BRITAIN; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MASS SCREENING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS;

EID: 84862614475     PISSN: 13665278     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta16240     Document Type: Review

References (253)

1. Mackie AD, Thornton SJ, Edenborough FP. Cystic fibrosis-related diabetes. Diabet Med 2003;20:425-436.
2. Ratjen F, Doring G. Cystic fibrosis. Lancet 2003;361:681-689.
3. Van den Berg JM, Kouwenberg JM, Heijerman HG. Demographics of glucose metabolism in cystic fibrosis. J Cyst Fibros 2009;8:276-279.
4. UK National Screening Committee. The UK NSC policy on cystic fibrosis screening in newborn. 2010. URL: www.screening.nhs.uk/cysticfibrosis-newborn (accessed 28 July 2010).
5. Warrell DA, Cox TM, Firth JD, Benz EJ, editors. Oxford textbook of medicine. 4th edn. Oxford: Oxford University Press; 2005.
6. Cystic Fibrosis Trust. Living with cystic fibrosis. 2010. URL: www.cftrust.org.uk/aboutcflivingwithcf(accessed 2 August 2010).
7. UK Cystic Fibrosis Trust Diabetes Working Group. Management of cystic fibrosis related diabetes mellitus. 2004. URL: www.cftrust.org.uk/aboutcf/publications/consensusdoc/diabetes.pdf
8. Brock DJ, Gilfillan A, Holloway S. The incidence of cystic fibrosis in Scotland calculated from heterozygote frequencies. Clin Genet 1998;53:47-5349.
9. Dodge JA, Morison S, Lewis PA, Coles EC, Geddes D, Russell G, et al. Incidence, population, and survival of cystic fibrosis in the UK, 1968-95. UK Cystic Fibrosis Survey Management Committee. Arch Dis Child 1997;77:493-496.
10. Li N, Pei P, Bu D-f, He B, Wang G-f. A novel CFTR mutation found in a Chinese patient with cystic fibrosis. Chin Med J 2006;119:103-109.
11. LabCorp. Genetic testing for cystic fibrosis. 2004. URL: www.labcorp.com/pdf/Cystic_Fibrosis_LabCapsule.pdf (accessed 2 August 2010).
12. Farrell PM. The prevalence of cystic fibrosis in the European Union. J Cyst Fibros 2008;7:450-453.
13. Scotet V, Audrezet M, Ferer C. Incidence of cystic fibrosis worldwide. J Cyst Fibros 2004;3:S115.
14. Koch C, Cuppens H, Rainisio M, Madessani U, Harms H, Hodson M, et al. European Epidemiologic Registry of Cystic Fibrosis (ERCF): comparison of major disease manifestations between patients with different classes of mutations. Pediatr Pulmonol 2001;31:1-12.
15. Milla CE, Warwick WJ, Moran A. Trends in pulmonary function in patients with cystic fibrosis correlate with the degree of glucose intolerance at baseline. Am J Respir Crit Care Med 2000;162:891-895.
16. Sawicki GS, Sellers DE, Robinson WM. High treatment burden in adults with cystic fibrosis: challenges to disease self-management. J Cyst Fibros 2009;8:91-6.
17. Andersen DH. Cystic fibrosis of the pancreas and its relation to celiac disease: a clinical and pathological study. Am J Dis Child 1938;56:344-399.
18. Cystic Fibrosis Foundation. Patient Registry: Annual Data Report. 2008. URL: www.cff.orgLivingWithCF/QualityImprovement/PatientRegistryReport(accesse d 28 July 2010).
19. Dodge JA, Lewis PA, Stanton M, Wilsher J. Cystic fibrosis mortality and survival in the UK: 1947-2003. Eur Respir J 2007;29:522-526.
20. UK Cystic Fibrosis Registry. Annual Data Report. 2008. URL: www.cftrust.org.uk/aboutcf/publications/cfregistryreports(accessed 13 September 2010).
21. Kulich M, Rosenfeld M, Goss CH, Wilmott R. Improved survival among young patients with cystic fibrosis. J Pediatr 2003;142:631-636.
22. Lewis PA, Morison S, Dodge JA, Geddes D, Coles EC, Russell G, et al. Survival estimates for adults with cystic fibrosis born in the United Kingdom between 1947 and 1967. The UK Cystic Fibrosis Survey Management Committee. Thorax 1999;54:420-422.
23. Dodge JA, Lewis PA. Cystic fibrosis is no longer an important cause of childhood death in the UK. Arch Dis Child 2005;90:547.
24. Edenborough FP, Mackenzie WE, Stableforth DE. The outcome of 72 pregnancies in 55 women with cystic fibrosis in the United Kingdom 1977-1996. BJOG 2000;107:254-61.
25. Gillet D. Cystic fibrosis and pregnancy. Report from French data (1980-1999). BJOG 2002;109:912-918.
26. McMullen AH, Pasta DJ, Frederick PD, Konstan MW, Morgan WJ, Schechter MS, et al. Impact of pregnancy on women with cystic fibrosis. Chest 2006;129:706-711.
27. Canadian Cystic Fibrosis Foundation. Canadian Cystic Fibrosis Patient Data Registry Report. 2007. URL: www.cysticfibrosis.ca/assets/files/pdf/CPDR_ReportE.pdf (accessed 2 August 2010).
28. Shwachman H, Kulczycki LL. Long-term study of one hundred five patients with cystic fibrosis; studies made over a five- to fourteen-year period. AMA J Dis Child 1958;96:6-15.
29. Cystic Fibrosis Australia. Cystic Fibrosis in Australia: 11th Annual Report from the Australian Cystic Fibrosis Data Registry. 2008. URL: www.cysticfibrosis.org.au/projects/dataregistry(accessed 2 August 2010).
30. O'Riordan SM, Dattani MT, Hindmarsh PC. Cystic fibrosis-related diabetes in childhood. Horm Res Paediatr 2010;73:15-24.
31. Elston C, Fairhurst M, Scott S, Bridges N, Shotliff K, Gyi K. Presence of diabetic complications in an adult cystic fibrosis population. Pediatr Pulmonol 2007;396.
32. Finkelstein SM, Wielinski CL, Elliott GR, Warwick WJ, Barbosa J, Wu SC, et al. Diabetes mellitus associated with cystic fibrosis. J Pediatr 1988;112:373-377.
33. Lanng S, Hansen A, Thorsteinsson B, Nerup J, Koch C. Glucose tolerance in patients with cystic fibrosis: 5-year prospective-study. BMJ 1995;311:655-659.
34. Adler A, Bilton D, Haworth C, Gunn E, Shine B. Epidemiology of cystic fibrosis-related diabetes - Results from a British Cohort. Pediatr Pulmonol 2007;363-364.
35. Rosenecker J, Eichler I, Kuhn L, Harms HK, von der Hardt H. Genetic Determination of Diabetes-Mellitus in Patients with Cystic-Fibrosis. J Pediatr 1995;127:441-443.
36. Marshall BC, Butler SM, Stoddard M, Moran AM, Liou TG, Morgan WJ. Epidemiology of cystic fibrosis-related diabetes. J Pediatr 2005;146:681-687.
37. Moran A, Doherty L, Wang X, Thomas W. Abnormal glucose metabolism in cystic fibrosis. J Pediatr 1998;133:10-17.
38. Moran A, Dunitz J, Nathan B, Saeed A, Holme B, Thomas W. Cystic fibrosis related diabetes: current trends in prevalence, incidence and mortality. Diabetes Care 2009;32:1626-1631.
39. Rana M. Population-based incidence of CFRD in NSW and ACT, Australia. Diabetes 2010;59:A300.
40. Droumaguet C, Elie C, Mosnier-Pudar H, Pesce F, Desmazes-Dufeu N, Hubert D. Risk of diabetes in a cohort of 243 adults with cystic fibrosis. J Cyst Fibros 2005;4:S81.
41. Hodson ME. Diabetes mellitus and cystic fibrosis. Bailliere Clin Endocrinol Metabol 1992;6:797-805.
42. Adler A, Shine B, Haworth C. Genetic determinants and epidemiology of cystis fibrosisrelated diabetes: results from a British cohort of children and adults. Diabetes Care 2008;31:1789-1794.
43. Cucinotta D, De Luca F, Scoglio R, Lombardo F, Sferlazzas C, Di Benedetto A, et al. Factors affecting diabetes mellitus onset in cystic fibrosis: evidence from a 10-year follow-up study. Acta Paediatr 1999;88:389-393.
44. Fischman D, Nookala VK. Cystic fibrosis-related diabetes mellitus: etiology, evaluation, and management. Endocr Pract 2008;14:1169-1179.
45. Alves C, Lima DS, Cardeal M, Santana A. Low prevalence of glucose intolerance in racially mixed children with cystic fibrosis. Pediatr Diabetes 2010;11:493-497.
46. Gilljam M, Ellis L, Corey M, Zielenski J, Durie P, Tullis DE. Clinical manifestations of cystic fibrosis among patients with diagnosis in adulthood. Chest 2004;126:1215-24.
47. Blackman SM, Hsu S, Ritter SE, Naughton KM, Wright FA, Drumm ML, et al. A susceptibility gene for type 2 diabetes confers substantial risk for diabetes complicating cystic fibrosis. Diabetologia 2009;52:1858-1865.
48. Yung B, Noormohamed FH, Kemp M, Hooper J, Lant AF, Hodson ME. Cystic fibrosis-related diabetes: the role of peripheral insulin resistance and beta-cell dysfunction. Diabet Med 2002;19:221-226.
49. Dobson L, Sheldon CD, Hattersley AT. Understanding cystic-fibrosis-related diabetes: best thought of as insulin deficiency? J R Soc Med 2004;97(Suppl. 44):26-35.
50. Couce M, Obrien TD, Moran A, Roche PC, Butler PC. Diabetes mellitus in cystic fibrosis is characterized by islet amyloidosis. J Clin Endocrinol Metabol 1996;81:1267-1272.
51. Zirbes J, Milla CE. Cystic fibrosis related diabetes. Paediatr Respir Rev 2009;10:118-123.
52. Schwarzenberg SJ, Walk D, Thomas W, Milla C, Olsen TW, Moran A, et al. Microvascular complications in cystic fibrosis-related diabetes. Diabetes Care 2007;30:1056-1061.
53. Black C, Cummins E, Royle P, Philip S, Waugh N. The clinical effectiveness and costeffectiveness of inhaled insulin in diabetes mellitus: a systematic review and economic evaluation. Health Technol Assess 2007;11(33).
54. Nousia-Arvanitakis S, Galli-Tsinopoulou A, Karamouzis M. Insulin improves clinical status of patients with cystic-fibrosis-related diabetes mellitus. Acta Paediatr 2001;90:515-519.
55. Brunzell C, Hardin DS, Moran A, Schindler T, Schissel K. Managing cystic fibrosis-related diabetes "(CFRD)": an instruction guide for patients and families. 4th edn. 2009. URL: www.cff.org/LivingWithCF/StayingHealthy/Diet/Diabetes(accessed 2 August 2010).
56. Tierney S, Deaton C, Webb K, Jones A, Dodd M, McKenna D, et al. Isolation, motivation and balance: living with type 1 or cystic fibrosis-related diabetes. J Clin Nurs 2008;17:235-243.
57. Milla CE, Billings J, Moran A. Diabetes is associated with dramatically decreased survival in female but not male subjects with cystic fibrosis. Diabetes Care 2005;28:2141-2144.
58. Miller RJ, Tildesley HD, Wilcox PG, Zhang H, Kreisman SH. Sex disparities in effects of cystic fibrosis-related diabetes on clinical outcomes: a matched study. Can Respir J 2008;15:291-4.
59. Srivastava S, Gyi K, Bilton D, Hodson M. Impact of cystic fibrosis related diabetes on survival in adult patients with cystic fibrosis at a single uk centre. Pediatr Pulmonol 2008;43:442-443.
60. Sims EJ, Green MW, Mehta A. Decreased lung function in female but not male subjects with established cystic fibrosis-related diabetes. Diabetes Care 2005;28:1581-1587.
61. Kampfert C, Holl RW, Marquart A, Ballmann M. Is earlier development of CFRD one possible reason for worse clinical findings in women with CFRD? J Cyst Fibros 2006;5:S63.
62. Chamnan P, Shine BS, Haworth CS, Bilton D, Adler AI. Diabetes as a determinant of mortality in cystic fibrosis. Diabetes Care 2010;33:311-316.
63. Yung B, Hodson ME. Diabetes in cystic fibrosis. J R Soc Med 1999;92(Suppl. 37):35-40.
64. Adler AI, Shine B, Haworth C, Leelarathna L, Bilton D. Hyperglycemia and death in cystic fibrosis-related diabetes. Diabetes Care 2011;34:2.
65. George PM, Banya W, Pareek N, Bilton D, Cullinan P, Hodson ME, et al. Improved survival at low lung function in cystic fibrosis: cohort study from 1990 to 2007. BMJ 2011;342:d1008.
66. Andersen HU, Lanng S, Pressler T, Laugesen CS, Mathiesen ER. Cystic fibrosisrelated diabetes: the presence of microvascular diabetes complications. Diabetes Care 2006;29:2660-2663.
67. Van den Berg JM, Morton AM, Kok SW, Pijl H, Conway SP, Heijerman HG. Microvascular complications in patients with cystic fibrosis-related diabetes (CFRD). J Cyst Fibros 2008;7:515-519.
68. Costa M, Potvin S, Berthiaume Y, Gauthier L, Jeanneret A, Lavoie A, et al. Diabetes: a major co-morbidity of cystic fibrosis. Diabetes Metab 2005;31:221-232.
69. Dobson L, Stride A, Bingham C, Elworthy S, Sheldon CD, Hattersley AT. Microalbuminuria as a screening tool in cystic fibrosis-related diabetes. Pediatr Pulmonol 2005;39:103-107.
70. Moran A. Abnormal glucose tolerance in CF: when should we offer diabetes treatment? Pediatr Diabetes 2009;10:159-161.
71. Georgiopoulou VV, Denker A, Bishop KL, Brown JM, Hirsh B, Wolfenden L, et al. Metabolic abnormalities in adults with cystic fibrosis. Respirology 2010;15:823-9.
72. Rhodes B, Nash EF, Tullis E, Pencharz PB, Brotherwood M, Dupuis A, et al. Prevalence of dyslipidemia in adults with cystic fibrosis. J Cyst Fibros 2010;9:24-8.
73. Cheung MS, Bridges NA, Prasad SA, Francis J, Carr SB, Suri R, et al. Growth in children with cystic fibrosis-related diabetes. Pediatr Pulmonol 2009;44:1223-1225.
74. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-553.
75. Wilkinson JD, Craigie IP, Allison G, Gallacher C, Crocker J, Kent S. Investigating suspected CF-related diabetes mellitus utilising serial capillary blood glucose profiling. J Cyst Fibros 2008;7:S83.
76. Wong TY, Liew G, Tapp RJ, Schmidt MI, Wang JJ, Mitchell P, et al. Relation between fasting glucose and retinopathy for diagnosis of diabetes: three population-based cross-sectional studies. Lancet 2008;371:736-743.
77. Carpenter S, Grasemann H. Evolution of glucose intolerance in adolescent CF patients. J Cyst Fibros 2007;6:S50.
78. Thorsteinsson B, Lanng S, Hansen A, Nerup J, Koch C. Glucose tolerance in cystic fibrosis: a 5-year prospective study. Diabetologia 1995;38:A13.
79. Sterescu AE, Rhodes B, Jackson R, Dupuis A, Hanna A, Wilson DC, et al. Natural history of glucose intolerance in patients with cystic fibrosis: ten-year prospective observation program. J Pediatr 2010;156:613-617.
80. Allen HF, Klingensmith GJ, Gay EC, Hamman RF. Identification and treatment of cystic fibrosis-related diabetes: a survey of current medical practice in the US. Diabetes Care 1998;21:943-948.
81. Mohan K, Miller H, Burhan H, Ledson MJ, Walshaw MJ. Management of cystic fibrosis related diabetes: A survey of UK cystic fibrosis centers. Pediatr Pulmonol 2008;43:642-647.
82. International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009;32:1327-1334.
83. Von Drygalski A, Biller J. Anemia in cystic fibrosis: incidence, mechanisms, and association with pulmonary function and vitamin deficiency. Nutr Clin Pract 2008;23:557-563.
84. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003;26:881-5.
85. Australia and New Zealand Horizon Scanning Network (ANZHSN). Continuous glucose monitoring devices. 2006. URL: http://nzhta.chmeds.ac.nz/publications/finalcgmd.pdf (accessed 2 August 2010).
86. McKeever TM, Weston PJ, Hubbard R, Fogarty A. Lung function and glucose metabolism: an analysis of data from the Third National Health and Nutrition Examination Survey. Am J Epidemiol 2005;161:546-56.
87. Gerich JE. Clinical significance, pathogenesis, and management of postprandial hyperglycemia. Arch Intern Med 2003;163:1306-1316.
88. Hanefeld M, Koehler C, Schaper F, Fuecker K, Henkel E, Temelkova-Kurktschiev T. Postprandial plasma glucose is an independent risk factor for increased carotid intima media thickness in non-diabetic individuals. Atherosclerosis 1999;144:229-235.
89. Shwachman H, Leubner H, Catzel P. Mucoviscidosis. Adv Pediatr 1955;7:249-323.
90. Moran A. Cystic fibrosis-related diabetes: an approach to diagnosis and management. Pediatr Diabetes 2000;1:41-48.
91. Sheldon CD, Dobson L. Insulin deficiency and diabetes related to cystic fibrosis. In Hodson M, Bush A, Geddes D, editors. Cystic fibrosis. London: Hodder Arnold; 2007. pp. 241-51.
92. WHO Study Group. Diabetes mellitus: report of a WHO Study Group. Technical Report Series No. 727. 1985. URL: http://whqlibdoc.who.int/trs/WHO_TRS_727.pdf (accessed 2 August 2010).
93. Laguna T, Nathan BM, Moran A. Managing diabetes in cystic fibrosis. Diabetes Obes Metabol 2010;12:858-864.
94. Hardin DS, Leblanc A, Lukenbaugh S, Seilheimer DK. Insulin resistance is associated with decreased clinical status in cystic fibrosis. J Pediatr 1997;130:948-956.
95. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979;28:1039-1057.
96. Alberti KG. The clinical implications of impaired glucose tolerance. Diabet Med 1996;13:927-937.
97. Rushforth NB, Miller M, Bennett PH. Fasting and two-hour post-load glucose levels for the diagnosis of diabetes. The relationship between glucose levels and complications of diabetes in the Pima Indians. Diabetologia 1979;16:373-379.
98. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-1197.
99. Brodsky J, Dougherty S, Makani R, Rubenstein RC, Kelly A. Elevation of 1-hour plasma glucose during oral glucose tolerance testing is associated with worse pulmonary function in cystic fibrosis. Diabetes Care 2011;34:292-295.
100. Moran A. Highlights of the February 1998 consensus conference on CFRD. Pediatr Pulmonol 1998;17:104-105.
101. Moran A, Becker D, Casella SJ, Gottlieb PA, Kirkman MS, Marshall BC, et al. Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis-related diabetes: a technical review. Diabetes Care 2010;33:2677-83.
102. Moran A, Hardin D, Rodman D, Allen HF, Beall RJ, Borowitz D, et al. Diagnosis, screening and management of cystic fibrosis related diabetes mellitus: a consensus conference report. Diabetes Res Clin Pract 1999;45:61-73.
103. Frohnert BI, Ode KL, Moran A, Nathan BM, Laguna T, Holme B, et al. Impaired fasting glucose in cystic fibrosis. Diabetes Care 2010;33:2660-2664.
104. Lohr M, Goertchen P, Nizze H, Gould NS, Gould VE, Oberholzer M, et al. Cystic fibrosis associated islet changes may provide a basis for diabetes. An immunocytochemical and morphometrical study. Virchows Arch A Pathol Anat Histopathol 1989;414:179-85.
105. WHO Expert Committee. WHO Expert Committee on diabetes mellitus. Second Report. Technical Report Series 646. 1980 http://whqlibdoc.who.int/trs/WHO_TRS_646.pdf (accessed 2 August 2010).
106. Reichard P, Berglund B, Britz A, Cars I, Nilsson BY, Rosenqvist U. Intensified conventional insulin treatment retards the microvascular complications of insulin-dependent diabetes mellitus (IDDM): the Stockholm Diabetes Intervention Study (SDIS) after 5 years. J Intern Med 1991;230:101-108.
107. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986.
108. Bouter KP, Diepersloot RJ, van Romunde LK, Uitslager R, Masurel N, Hoekstra JB, et al. Effect of epidemic influenza on ketoacidosis, pneumonia and death in diabetes mellitus: a hospital register survey of 1976-1979 in the Netherlands. Diabetes Res Clin Pract 1991;12:61-68.
109. Fine MJ, Smith MA, Carson CA, Mutha SS, Sankey SS, Weissfeld LA, et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 1996;275:134-141.
110. Kornum JB, Thomsen RW, Riis A, Lervang HH, Schonheyder HC, Sorensen HT. Diabetes, glycemic control, and risk of hospitalization with pneumonia: a population-based case- control study. Diabetes Care 2008;31:1541-545.
111. Koziel H, Koziel MJ. Pulmonary complications of diabetes mellitus. Pneumonia. Infect Dis Clin North Am 1995;9:65-96.
112. Ardigo D, Valtuena S, Zavaroni I, Baroni MC, Delsignore R. Pulmonary complications in diabetes mellitus: the role of glycemic control. Curr Drug Targets Inflamm Allergy 2004;3:455-458.
113. Niranjan V, McBrayer DG, Ramirez LC, Raskin P, Hsia CC. Glycemic control and cardiopulmonary function in patients with insulin-dependent diabetes mellitus. Am J Med 1997;103:504-513.
114. Chance WW, Rhee C, Yilmaz C, Dane DM, Pruneda ML, Raskin P, et al. Diminished alveolar microvascular reserves in type 2 diabetes reflect systemic microangiopathy. Diabetes Care 2008;31:1596-601.
115. Weynand B, Jonckheere A, Frans A, Rahier J. Diabetes mellitus induces a thickening of the pulmonary basal lamina. Respiration 1999;66:14-19.
116. Davis WA, Knuiman M, Kendall P, Grange V, Davis TM. Glycemic exposure is associated with reduced pulmonary function in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Care 2004;27:752-7.
117. Baker EH, Wood DM, Brennan AL, Clark N, Baines DL, Philips BJ. Hyperglycaemia and pulmonary infection. Proc Nutr Soc 2006;65:227-35.
118. Philips BJ, Meguer JX, Redman J, Baker EH. Factors determining the appearance of glucose in upper and lower respiratory tract secretions. Intensive Care Med 2003;29:2204-10.
119. Koch C, Rainisio M, Madessani U, Harms HK, Hodson ME, Mastella G, et al. Presence of cystic fibrosis-related diabetes mellitus is tightly linked to poor lung function in patients with cystic fibrosis: Data from the European Epidemiologic Registry of Cystic Fibrosis. Pediatr Pulmonol 2001;32:343-50.
120. Rosenecker J, Eichler I, Barmeier H, von der Hardt H. Diabetes mellitus and cystic fibrosis: comparison of clinical parameters in patients treated with insulin versus oral glucoselowering agents. Pediatr Pulmonol 2001;32:351-5.
121. Adler AI, Gunn E, Haworth CS, Shine BS, Diana B. Diabetes mellitus and impaired glucose tolerance are associated with poor pulmonary function in adults with cystic fibrosis. Diabetes 2007;56:A267.
122. Lanng S, Thorsteinsson B, Nerup J, Koch C. Influence of the development of diabetes mellitus on clinical status in patients with cystic fibrosis. Eur J Pediatr 1992;151:684-7.
123. Barrett-Connor E, Frette C. NIDDM, impaired glucose tolerance, and pulmonary function in older adults. The Rancho Bernardo Study. Diabetes Care 1996;19:1441-4.
124. Lange P, Groth S, Kastrup J, Mortensen J, Appleyard M, Nyboe J, et al. Diabetes mellitus, plasma glucose and lung function in a cross-sectional population study. Eur Respir J 1989;2:14-19.
125. Lawlor DA, Ebrahim S, Smith GD. Associations of measures of lung function with insulin resistance and Type 2 diabetes: findings from the British Women's Heart and Health Study. Diabetologia 2004;47:195-203.
126. Lazarus R, Sparrow D, Weiss ST. Baseline ventilatory function predicts the development of higher levels of fasting insulin and fasting insulin resistance index: the Normative Aging Study. Eur Respir J 1998;12:641-5.
127. Yeh HC, Punjabi NM, Wang NY, Pankow JS, Duncan BB, Cox CE, et al. Cross-sectional and prospective study of lung function in adults with type 2 diabetes: the Atherosclerosis Risk in Communities (ARIC) study. Diabetes Care 2008;31:741-6.
128. Schaedel C, de Monestsrol I, Hjelte L, Johannesson M, Kornfalt R, Lindblad A, et al.Predictors of deterioration of lung function in cystic fibrosis. Pediatr Pulmonol 2002;33:483-91.
129. Brown J, Elston C, Driver R, Hitman GA, Kuitert LM. Decline in lung function and BMI prior to the diagnosis of CFRD and the impact of gender. J Cyst Fibros 2006;5:S63.
130. Drummond RS, Love A, Semple K, Bicknell S, Ross E, Small M, et al. Insulin therapy ameliorates loss of lung function in cystic fibrosis and should be commenced when impaired glucose tolerance is present. Diabetes 2006;55:A75.
131. Wood DM, Brennan AL, Philips BJ, Baker EH. Effect of hyperglycaemia on glucose concentration of human nasal secretions. Clin Sci 2004;106:527-33.
132. Brennan AL, Gyi KM, Clark N, Fisher DA, Wood DM, Baines DL, et al. Detection of increased glucose concentrations in lower airway secretions from people with cystic fibrosis. Thorax 2005;60:II93.
133. Brennan AL, Gyi KM, Wood DM, Johnson J, Holliman R, Baines DL, et al. Airway glucose concentrations and effect on growth of respiratory pathogens in cystic fibrosis. J Cyst Fibros 2007;6:101-9.
134. Lanng S, Thorsteinsson B, Nerup J, Koch C. Diabetes mellitus in cystic fibrosis: effect of insulin therapy on lung function and infections. Acta Paediatr 1994;83:849-53.
135. Rafii M, Chapman K, Stewart C, Kelly E, Hanna A, Wilson DC, et al. Changes in response to insulin and the effects of varying glucose tolerance on whole-body protein metabolism in patients with cystic fibrosis. Am J Clin Nutr 2005;81:421-6.
136. Onady GM, Stolfi A. Insulin and oral agents for managing cystic fibrosis-related diabetes. Cochrane Database Syst Rev 2009;3.CD004730.
137. National Institute for Health and Clinical Excellence (NICE). Imatinib for chronic myeloid leukaemia (TA50). London: NICE; 2002.
138. Dobson L, Hattersley AT, Tiley S, Elworthy S, Oades PJ, Sheldon CD. Clinical improvement in cystic fibrosis with early insulin treatment. Arch Dis Child 2002;87:430-1.
139. Sulli N, Bertasi S, Zullo S, Shashaj B. Use of continuous subcutaneous insulin infusion in patients with cystic fibrosis related diabetes: three case reports. J Cyst Fibros 2007;6:237-40.
140. The DECODE study group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe. Lancet 1999;354:617-21.
141. Moran A, Pekow P, Grover P, Zorn M, Slovis B, Pilewski J, et al. Insulin therapy to improve BMI in cystic fibrosis related diabetes without fasting hyperglycemia: results of the CFRDT Trial. Diabetes Care 2009;32:1783-8.
142. Culler FL, Mckean LP, Buchanan CN, Caplan DB, Meacham LR. Glipizide treatment of patients with cystic-fibrosis and impaired glucose-tolerance. J Pediatr Gastroenterol Nutr 1994;18:375-8.
143. Bertele-Harms RM, Harms HK. Sulfonylurea (SU) in the treatment of CF related diabetes mellitus (CFDM). A 15 year experience. Pediatr Pulmonol 1996;22:380A.
144. Kentrup H, Bongers H, Spengler M, Kusenbach G, Skopnik H. Efficacy and safety of acarbose in patients with cystic fibrosis and impaired glucose tolerance. Eur J Pediatr 1999;158:455-9.
145. Moran A, Phillips J, Milla C. Insulin and glucose excursion following premeal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care 2001;24:1706-10.
146. Rolon MA, Benali K, Munck A, Navarro J, Clement A, Tubiana-Rufi N, et al. Cystic fibrosisrelated diabetes mellitus: clinical impact of prediabetes and effects of insulin therapy. Acta Paediatr 2001;90:860-7.
147. Ballmann M, Mueller-Brandes C. Longitudinal follow-up of clinical and laboratory data in pediatric patients with cystic fibrosis related diabetes mellitus (CFRD) after initial treatment with an oral antidiabetic drug (Glibenclamid). Pediatr Pulmonol 2003;36:352.
148. Boyle BJ, Henderson P, Bicknell S, Small M, Jones GC. Early insulin treatment improves weight and lung function in patients with cystic fibrosis. Diabet Med 2004;21:103.
149. Franzese A, Spagnuolo MI, Sepe A, Valerio G, Mozzillo E, Raia V. Can glargine reduce the number of lung infections in patients with cystic fibrosis-related diabetes? Diabetes Care 2005;28:2333.
150. Minicucci L, De Alessandri A, Casciaro R, Burlando O, Lugani F, Poggi E, et al. Insulin glargine (IG) for therapy of cystic fibrosis related diabetes (CFRD) and impaired glucose tolerance (IGT) in cystic fibrosis (CF) patients (pts). J Cyst Fibros 2005;4:32.
151. Bizzarri C, Lucidi V, Ciampalini P, Bella S, Russo B, Cappa M. Clinical effects of early treatment with insulin glargine in patients with cystic fibrosis and impaired glucose tolerance. J Endocrinol Invest 2006;29:RC1-4.
152. Drummond RS, Love A, Semple K, Bicknell S, Ross E, Small M, et al. The favourable effect of insulin upon pulmonary function in patients with cystic fibrosis correlates with the degree of glucose intolerance at baseline. Diabet Med 2006;23:43.
153. Hardy J, Dixon M, Bone M, Vyas J, David TJ, Patel L. Does insulin treatment influence growth and lung function in children with abnormal oral glucose tolerance test (OGTT) but normal fasting glucose? J Cyst Fibros 2006;5:S64.
154. McGinnity T, Harms B, Trevellyan N, Connett GJ. Once daily long acting insulin achieves good glycaemic control in Cystic Fibrosis related diabetes (CFRD). J Cyst Fibros 2006;5:S62.
155. Onady GM, Langdon LJ. Insulin versus oral agents in the management of cystic fibrosis related diabetes: a case based study. BMC Endocr Disord 2006;6:4.
156. Drummond RS, Carty D, Small M, Jones GC. The characterisation of hypoglycaemia in insulin treated patients with cystic fibrosis. Diabet Med 2007;24:8.
157. Grover P, Thomas W, Moran A. Glargine versus NPH insulin in cystic fibrosis related diabetes. J Cyst Fibros 2008;7:134-6.
158. Mohan K, Israel KL, Miller H, Grainger R, Ledson MJ, Walshaw MJ. Long-term effect of insulin treatment in cystic fibrosis-related diabetes. Respiration 2008;76:181-6.
159. Hardin DS, Rice J, Rice M, Rosenblatt R. Use of the insulin pump in treating cystic fibrosis related diabetes. J Cyst Fibros 2009;8:174-8.
160. Mozzillo E, Franzese A, Valerio G, Sepe A, De S, I, Mazzarella G, et al. One-year glargine treatment can improve the course of lung disease in children and adolescents with cystic fibrosis and early glucose derangements. Pediatr Diabetes 2009;10:162-7.
161. Hameed S, Morton JR, Field PI, Belessis Y, Yoong T, Katz T, et al. Once daily insulin detemir in cystic fibrosis with insulin deficiency [published online ahead of print 14 April 2011]. Arch Dis Child 2011. doi:10.1136/adc.2010.204636.
162. Minicucci L, Casciaro R, De Alessandri A, Haupt M, Caso M, Lucidi V, et al. Efficacy of slow release insulin in patients with cystic fibrosis and glucide intolerance. J Cyst Fibros 2009;8:S82.
163. Hameed S, Morton JR, Jaffe A, Field PI, Belessis Y, Yoong T, et al. Once-daily insulin detemir in cystic fibrosis related diabetes (CFRD). Horm Res 2009;72:160-1.
164. Brennan AL, Geddes DM, Gyi KM, Baker EH. Clinical importance of cystic fibrosis-related diabetes. J Cyst Fibros 2004;3:209-22.
165. de Valk HW, van der Graaf EA. Cystic fibrosis-related diabetes in adults: where can we go from here? Rev Diabet Stud 2007;4:6-12.
166. Lanng S. Glucose intolerance in cystic fibrosis patients. Paediatr Respir Rev 2001;2:253-9.
167. Moran A. Diagnosis, screening, and management of cystic fibrosis-related diabetes. Curr Diab Rep 2002;2:111-15.
168. O'Riordan SM, Robinson PD, Donaghue KC, Moran A. Management of cystic fibrosisrelated diabetes. Pediatr Diabetes 2008;9:338-44.
169. Nathan BM, Laguna T, Moran A. Recent trends in cystic fibrosis-related diabetes. Current Opinion Endocrinol Diabetes Obes 2010;17:335-41.
170. Rana M, Munns CF, Selvadurai H, Donaghue KC, Craig ME. Cystic fibrosis-related diabetes in children-gaps in the evidence? Nature Reviews Endocrinology 2010;6:371-8.
171. O'Riordan SM, Robinson PD, Donaghue KC, Moran A. Management of cystic fibrosisrelated diabetes in children and adolescents. Pediatr Diabetes 2009;10(Suppl. 12):43-50.
172. Moran A, Brunzell C, Cohen RC, Katz M, Marshall BC, Onady G, et al. Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care 2010;33:2697-708.
173. Ode KL, Frohnert B, Laguna T, Phillips J, Holme B, Regelmann W, et al. Oral glucose tolerance testing in children with cystic fibrosis. Pediatr Diabetes 2010;11:487-92.
174. Buck C, Thon A, Wolf A, Kohne E, Holl RW. Diagnosis of diabetes mellitus in cystic fibrosis (CF) - role of blood sugar, HbA(1c) and oral glucose tolerance test [German]. Monatsschr Kinderheilkd 2000;148:698-701.
175. Brennan AL, Hodson ME, Geddes DM, Gyi KM, Baker EH. Describing the relationship between HbA1c and mean plasma glucose in people with cystic fibrosis. J Cyst Fibros 2004;3:81.
176. Brennan AL, Gy KM, Wood DM, Hodson ME, Geddes DM, Baker EH. Relationship between glycosylated haernoglobin and mean plasma glucose concentration in cystic fibrosis. J Cyst Fibros 2006;5:27-31.
177. Haesebaert J, Bourdy S, Perceval M, Chabloz C, Nove-Josserand R, Reix P, et al. [Screening and management of glucose metabolism disorders in cystic fibrosis patients. Practices survey in 4 French reference centers.] Arch Pediatr 2009;16:1435-42.
178. Khammar A, Stremler N, Dubus JC, Gross G, Sarles J, Reynaud R. [Value of continuous glucose monitoring in screening for diabetes in cystic fibrosis.] Arch Pediatr 2009;16:1540-6.
179. Whiting P, Rutjes AW, Dinnes J, Reitsma J, Bossuyt PM, Kleijnen J. Development and validation of methods for assessing the quality of diagnostic accuracy studies. Health Technol Assess 2004;8(25).
180. Whiting P, Rutjes AW, Dinnes J, Reitsma JB, Bossuyt PM, Kleijnen J. A systematic review finds that diagnostic reviews fail to incorporate quality despite available tools. J Clin Epidemiol 2005;58:1-12.
181. MedCalc Software. MedCalc. 2011. URL: wwwmedcalc.org/calc/diagnostic_test.php (accessed 22 June 2011).
182. Holl RW, Buck C, Babka C, Wolf A, Thon A. HbA1c is not recommended as a screening test for diabetes in cystic fibrosis. Diabetes Care 2000;23:126.
183. De Luca F, Arrigo T, Nibali SC, Sferlazzas C, Gigante A, DiCesare E, et al. Insulin secretion, glycosylated hemoglobin and islet cell antibodies in cystic-fibrosis children and adolescents with different degrees of glucose tolerance. Horm Metab Res 1991;23:495-8.
184. De Schepper J, Dab I, Derde MP, Loeb H. Oral glucose tolerance testing in cystic fibrosis: correlations with clinical parameters and glycosylated hemoglobin determinations. Eur J Pediatr 1991;150:403-6.
185. Lee KM, Miller RJ, Rosenberg FM, Kreisman SH. Evaluation of glucose tolerance in cystic fibrosis: comparison of 50-g and 75-g tests. J Cyst Fibros 2007;6:274-6.
186. Magni A. Screening tests for glucose metabolism abnormalities in cystic fibrosis. Eur J Lab Med 1996;4:6-10.
187. Moreau F, Weiller MA, Rosner V, Weiss L, Hasselmann M, Pinget M, et al. Continuous glucose monitoring in cystic fibrosis patients according to the glucose tolerance. Horm Metab Res 2008;40:502-6.
188. Robert JJ, Grasset E, de Montalembert M, Chevenne D, Deschamps I, Boitard C, et al. [Factors for Glucose-Intolerance in Cystic-Fibrosis.] [French]. Arch Fr Pediatr 1992;49:17-22.
189. Yung B, Kemp M, Hooper J, Hodson ME. Diagnosis of cystic fibrosis related diabetes: a selective approach in performing the oral glucose tolerance test based on a combination of clinical and biochemical criteria. Thorax 1999;54:40-3.
190. Scottish Intercollegiate Guidelines Network (SIGN). Management of diabetes. SIGN Publication No. 116. SIGN 2010. URL: wwwsign.ac.uk/guidelines/fulltext/116/index.html
191. De Simone I, Raia V, Sepe A, Valerio G, De Gregorio F, Buono P, et al. Early detection of glucose derangements in children with cystic fibrosis under ten years of age. Pediatr Diabetes 2009;10(Suppl.11):93.
192. Dobson L, Sheldon CD, Hattersley AT. Validation of interstitial fluid continuous glucose monitoring in cystic fibrosis. Diabetes Care 2003;26:1940-1.
193. Dobson L, Sheldon CD, Hattersley AT. Conventional measures underestimate glycaemia in cystic fibrosis patients. Diabet Med 2004;21:691-6.
194. Franzese A, Valerio G, Buono P, Spagnuolo MI, Sepe A, Mozzillo E, et al. Continuous glucose monitoring system in the screening of early glucose derangements in children and adolescents with cystic fibrosis. J Pediatr Endocrinol Metab 2008;21:109-16.
195. Jefferies C, Solomon M, Perlman K, Sweezey N, Daneman D. Continuous glucose monitoring in adolescents with cystic fibrosis. J Pediatr 2005;147:396-8.
196. O'Riordan S, Hoey H, George S, Costigan C. Can continuous glucose monitoring (CGMS) enhance the detection of CFRD in 167 cystic fibrosis children? Diabetes 2006;55:A17-18.
197. O'Riordan S, George S, Hoey H, Greally P, Costigan C, Canny G. Glucose homeostasis and continuous glucose monitoring in 167 children with cystic fibrosis. Diabet Med 2006;23:64.
198. O'Riordan SMP, Roche EF, George S, Hoey HMV, Costigan C. Continuous glucose monitoring (CGMS) enhances the detection of cystic fibrosis related diabetes (CFRD) in children with cystic fibrosis. Diabetologia 2007;50:S84-5.
199. Middleton PG, Bishop J. Oral glucose tolerance testing in CF adults: cross-sectional and longitudinal comparisons. J Cyst Fibros 2006;5:S62.
200. Solomon MP, Wilson DC, Corey M, Kalnins D, Zielenski J, Tsui LC, et al. Glucose intolerance in children with cystic fibrosis. J Pediatr 2003;142:128-32.
201. Hardin DS, Grilley K, Baron B, Hale KA. Accelerated red blood cell turnover can invalidate the use of haemoglobin A1c as a diagnostic test for cystic fibrosis related diabetes. Pediatr Res 1999;45:90A.
202. Allen HF. Potential impact of HbA1c determination on clinical decision making in patients with cystic fibrosis-related diabetes - reply to Hunkert et al. Diabetes Care 1999;22:1009-10.
203. Garagorri JM, Rodriguez G, Ros L, Sanchez A. Early detection of impaired glucose tolerance in patients with cystic fibrosis and predisposition factors. J Pediatr Endocrinol Metab 2001;14:53-60.
204. Al-Aloul M, Pandya S, Cowperthwaite C, Walshaw MJ, Ledson MJ. Post prandial glucose measurement in the assessment of CF related diabetes mellitus (CFRDM). J Cyst Fibros 2003;2:S78.
205. Mueller-Brandes C, Holl RW, Nastoll M, Ballmann M. New criteria for impaired fasting glucose and screening for diabetes in cystic fibrosis. Eur Respir J 2005;25:715-17.
206. Goldstein DE, Little RR, Wiedmeyer HM, England JD, Rohlfing CL, Wilke AL. Is glycohemoglobin testing useful in diabetes mellitus? Lessons from the diabetes control and complications trial. Clin Chem 1994;40:1637-40.
207. Goldstein DE, Little RR, Lorenz RA, Malone JI, Nathan D, Peterson CM. Tests of glycemia in diabetes. Diabetes Care 1995;18:896-909.
208. Tahara Y, Shima K. The response of GHb to stepwise plasma glucose change over time in diabetic patients. Diabetes Care 1993;16:1313-14.
209. Adler A, Shine B. Epidemiology of cystic fibrosis-related diabetes; results from a British cohort of children and adults. Diabetologia 2007;50:S34.
210. Abbott J. Health-related quality of life measurement in cystic fibrosis: advances and limitations. Chronic Respir Dis 2009;6:31-41.
211. Quittner AL. Measurement of quality of life in cystic fibrosis. Curr Opin Pulm Med 1998;4:326-31.
212. Tierney S, Webb K, Jones A, Dodd M, McKenna D, Rowe R, et al. Living with cystic fibrosis-related diabetes or type 1 diabetes mellitus: a comparative study exploring healthrelated quality of life and patients' reported experiences of hypoglycaemia. Chronic Illness 2008;4:278-88.
213. Hameed S, Morton JR, Jaffe A, Field PI, Belessis Y, Yoong T, et al. Early glucose abnormalities in cystic fibrosis are preceded by poor weight gain. Diabetes Care 2010;33:221-6.
214. UK National Screening Committee. Programme appraisal criteria: criteria for appraising the viability, effectiveness and appropriateness of a screening programme. 2012. URL: www.screening.nhs.uk/criteria (accessed 20 January 2012).
215. Barr HL, Britton J, Smyth AR, Fogarty AW. Association between socioeconomic status, sex, and age at death from cystic fibrosis in England and Wales (1959 to 2008): cross sectional study. BMJ 2011;343:461.
216. Allen HF. Glycosylated hemoglobin levels and new diagnostic criteria: should the oral glucose tolerance test be performed as a routine screening test for diabetes in cystic fibrosis patients? Response. Diabetes Care 1998;21:2199-200.
217. Bistritzer T. Hemoglobin A and pancreatic beta cell function in cystic fibrosis. Isr J Med Sci 1983;19:600-3.
218. Holl RW, Buck C, Cario H, Wolf A, Thon A, Kohne E, et al. Diagnosis of diabetes in cystic fibrosis and thalassemia major. Diabetes Care 1998;21:671-2.
219. Huot C, Fortin H, So VC, Gonthier M, Lamarre A. Screening for abnormal blood glucose metabolism in children and adolescents with cystic fibrosis. Diabetes 1997;46:399.
220. Lanng S, Thorsteinsson B, Nerup J, Koch C. Diabetes mellitus in cystic fibrosis: a ten-year prospective study. Diabetologia 2000;43:A27.
221. Ledson MJ, Mohan K, Dyce P, Miller H, Walshaw MJ. Comparison of the oral glucose tolerance test and serial glucose monitoring in CF patients. J Cyst Fibros 2007;6:394.
222. Liou TG, Brayshaw S, Brown M, Chatfield B, Jensen M, McDonald C, et al. Improving performance in the detection and management of CFRD in the Mountain West Consortium. Pediatr Pulmonol 2006;41:439.
223. Loo SWH, Matthews WJ, Gabbay KH. Glycosylated hemoglobin in cystic fibrosis: distribution and relationship to glucose intolerance. Pediatr Res 1979;13:478.
224. Mohan K, Miller H, Dyce P, Ledson MJ, Walshaw MJ. Comparison of the oral glucose tolerance test and serial glucose monitoring in cystic fibrosis patients. Thorax 2007;62:A102-3.
225. Richmond R, McKenna D, Tierney S, Rowe R, Dodd M, Jones A. Can patients at risk of cystic fibrosis-related diabetes be identified early? J Cyst Fibros 2008;7:S83.
226. Stutchfield PR, O'Halloran S, Teale JD, Isherwood D, Smith CS, Heaf D. Glycosylated haemoglobin and glucose intolerance in cystic fibrosis. Arch Dis Child 1987;62:805-10.
227. Verma A, Claridge A, Havelock T, Biesty J, McMenna D, Webb AK. Re-audit of the screening protocol for cystic fibrosis related diabetes (CFRD) in an adult centre. Thorax 2002;57:ii20.
228. Watson H, Barker H, Henman S, Lyon A, Haworth CS, Bilton D. Three day continuous subcutaneous glucose monitoring (CSGM) in the clinical management of adult patients with CF and diabetes (CFRD). J Cyst Fibros 2007;6:S49.
229. Yung B, Kemp M, Hooper J, Hodson M. Random blood glucose alone in the diagnosis of cystic fibrosis related diabetes. Lancet 1997;349:619.
230. Yung B. Should the oral glucose tolerance test be performed as a routine screening test for diabetes in cystic fibrosis patients? Response to Allen et al. and Holl et al. Diabetes Care 1998;21:2199-200.
231. Quittner AL, Buu A, Messer MA, Modi AC, Watrous M. Development and validation of The Cystic Fibrosis Questionnaire in the United States: a health-related quality-of-life measure for cystic fibrosis. Chest 2005;128:2347-54.
232. Riekert KA, Bartlett SJ, Boyle MP, Krishnan JA, Rand CS. The association between depression, lung function, and health-related quality of life among adults with cystic fibrosis. Chest 2007;132:231-7.
233. Urquhart DS, Field B, Bryon M, Jaffe A. Effects of lung function and exercise capacity on quality of life in cystic fibrosis using the UK cystic fibrosis questionnaire. Thorax 2007;62:A103-4.
234. Thomas C, Mitchell P, O'Rourke P, Wainwright C. Quality-of-life in children and adolescents with cystic fibrosis managed in both regional outreach and cystic fibrosis center settings in Queensland. J Pediatr 2006;148:508-16.
235. Klijn PH, van Stel HF, Quittner AL, van der NJ, Doeleman W, van der Schans CP, et al. Validation of the Dutch cystic fibrosis questionnaire (CFQ) in adolescents and adults. J Cyst Fibros 2004;3:29-36.
236. Gee L, Abbott J, Hart A, Conway SP, Etherington C, Webb AK. Associations between clinical variables and quality of life in adults with cystic fibrosis. J Cyst Fibros 2005;4:59-66.
237. Powers PM, Gerstle R, Lapey A. Adolescents with cystic fibrosis: family reports of adolescent health-related quality of life and forced expiratory volume in one second. Pediatrics 2001;107:E70.
238. Britto MT, Kotagal UR, Hornung RW, Atherton HD, Tsevat J, Wilmott RW. Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis. Chest 2002;121:64-72.
239. Sawyer MG. Health-related quality of life of children and adolescents with chronic illness: a two year prospective study. Qual Life Res 2004;13:1309-19.
240. Sawyer MG. A two-year prospective study of the health-related quality of life of children with chronic illness - The parents' perspective. Qual Life Res 2005;14:395-405.
241. Ingerski LM, Modi AC, Hood KK, Pai AL, Zeller M, Piazza-Waggoner C, et al. Health-related quality of life across pediatric chronic conditions. J Pediatr 2010;156:639-44.
242. Congleton J. Quality of life in adults with cystic fibrosis. Eur Respir Rev 1997;7:74-6.
243. Orenstein DM, Nixon PA, Ross EA, Kaplan RM. The quality of well-being in cystic fibrosis. Chest 1989;95:344-7.
244. Kotwicki RJ, Condra L, Vermeulen L, Wolf T, Douglas J, Farrell PM. Assessing the quality of life in children with cystic fibrosis. WMJ 2001;100:50-4.
245. Suri R, Metcalfe C, Wallis C, Bush A. Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respir Med 2007;101:254-60.
246. Eidt-Koch D, Mittendorf T, Greiner W. Cross-sectional validity of the EQ-5D-Y as a generic health outcome instrument in children and adolescents with cystic fibrosis in Germany. BMC Pediatr 2009;9:55.
247. de Jong W, Kaptein AA, vanderSchans CP, Mannes GPM, vanAalderen WMC, Grevink RG, et al. Quality of life in patients with cystic fibrosis. Pediatr Pulmonol 1997;23:95-100.
248. Bradley J, Dempster M, Wallace E, Elborn S. The adaptations of a quality of life questionnaire for routine use in clinical practice: the Chronic Respiratory Disease Questionnaire in cystic fibrosis. Qual Life Res 1999;8:65-71.
249. Goldbeck L, Zerrer S, Schmitz TG. Monitoring quality of life in outpatients with cystic fibrosis: feasibility and longitudinal results. J Cyst Fibros 2007;6:171-8.
250. Goldbeck L, Schmitz TG. Comparison of three generic questionnaires measuring quality of life in adolescents and adults with cystic fibrosis: the 36-item short form health survey, the quality of life profile for chronic diseases, and the questions on life satisfaction. Qual Life Res 2001;10:23-36.
251. Weiner JR, Toy EL, Sacco P, Duh MS. Costs, quality of life and treatment compliance associated with antibiotic therapies in patients with cystic fibrosis: a review of the literature. Exp Opin Pharmacother 2008;9:751-66.
252. Cruz I, Marciel KK, Quittner AL, Schechter MS. Anxiety and depression in cystic fibrosis. Semin Respir Crit Care Med 2009;30:569-78.
253. Quittner AL, Barker DH, Snell C, Grimley ME, Marciel K, Cruz I. Prevalence and impact of depression in cystic fibrosis. Curr Opin Pulm Med 2008;14:582-8.